8-K: Codexis Reports Mixed 2023 Results but Anticipates Growth in 2024

Codexis announced its fourth quarter and full year 2023 financial results, highlighting a decrease in overall revenue but anticipating product revenue growth in 2024 and a focus on their ECO Synthesis manufacturing platform.

Summary

• Codexis reported a decrease in total revenue for fiscal year 2023, with $70.1 million compared to $138.6 million in 2022, largely due to reduced enzyme sales related to PAXLOVID.
• Excluding PAXLOVID related sales, total revenue decreased by 2% to $62.0 million for fiscal year 2023.
• Product revenue, excluding PAXLOVID, decreased by 16% to $34.8 million for fiscal year 2023.
• However, fourth quarter 2023 showed a positive trend with a 42% increase in total revenue, excluding PAXLOVID, to $18.4 million compared to the same period in 2022.
• Product revenue, excluding PAXLOVID, increased by 69% to $9.9 million in the fourth quarter of 2023.
• The company's net loss for fiscal year 2023 was $76.2 million, or $1.12 per share, compared to a net loss of $33.6 million, or $0.51 per share, for fiscal year 2022.
• Codexis anticipates product revenue growth of at least 10% in 2024 compared to 2023, excluding PAXLOVID related sales.
• They also expect product revenue to be in the range of $38 million to $42 million and R&D revenue to be between $18 million and $22 million for 2024.
• The company projects that its current cash and cash equivalents will be sufficient to fund operations through positive cash flow, expected around the end of 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with a significant revenue decline in 2023 but positive growth in Q4 and a promising outlook for 2024. The strategic moves and partnerships are positive, but the financial losses and risks temper the overall sentiment.

Positives

• Codexis experienced a significant increase in revenue in the fourth quarter of 2023, with a 42% increase in total revenue excluding PAXLOVID sales.
• Product revenue, excluding PAXLOVID, increased by 69% in the fourth quarter of 2023.
• The company secured a $40 million loan facility, strengthening its financial position.
• Codexis has entered into strategic partnerships and licensing agreements with companies like Roche and Aldevron.
• They achieved a key technical milestone with gram-scale synthesis of oligonucleotides using their ECO Synthesis platform.
• The company is projecting a return to growth for its Pharmaceutical Manufacturing business in 2024.
• Codexis anticipates positive cash flow around the end of 2026.

Negatives

• Total revenue for fiscal year 2023 decreased significantly compared to 2022, primarily due to reduced PAXLOVID enzyme sales.
• Product revenue, excluding PAXLOVID, decreased by 16% for fiscal year 2023.
• The company reported a net loss of $76.2 million for fiscal year 2023, a significant increase from the $33.6 million loss in 2022.
• The company's R&D expenses were $58.9 million for fiscal year 2023.

Risks

• Codexis is dependent on its licensees and collaborators, and any termination of these agreements could negatively impact the company.
• The company may need additional capital in the future to expand its business.
• There is a risk that Codexis may not be able to successfully develop new technologies, such as the ECO Synthesis manufacturing platform.
• The company relies on a limited number of products and customers, and adverse market reception of these products could harm the business.
• Competitors with greater resources could develop products that make Codexis' offerings obsolete.
• Codexis must comply with debt covenants under its loan facility.
• The company's ability to accurately forecast financial and operational performance is a risk.
• Market and economic conditions could negatively impact Codexis' business, financial condition, and share price.

Future Outlook

Codexis anticipates product revenue growth of at least 10% in 2024, excluding PAXLOVID revenue, and expects to achieve positive cash flow around the end of 2026. They plan to focus on securing early access customers for their ECO Synthesis manufacturing platform and launching their dsRNA ligase program in the second half of 2024.

Management Comments

• We are thrilled with how we closed out 2023, and its quite clear that the strategic decisions we made last year are translating into real momentum as we kick off 2024.
• We're driving value from non-core assets by putting them in the hands of capable partners while we focus on unlocking the vast potential of the ECO Synthesis manufacturing platform and returning our foundational, revenue-generating Pharmaceutical Manufacturing business to double-digit growth this year.
• Our recently announced non-dilutive financing with Innovatus further strengthens our financial position by both buffering our cash runway and providing capital to fund our planned ECO Synthesis Innovation Lab to further test the ECO Synthesis manufacturing platform in a non-GMP setting.

Industry Context

This announcement comes as the RNA therapeutics market is experiencing significant growth, and Codexis is positioning itself to capitalize on this trend with its ECO Synthesis platform and dsRNA ligase program. The company's focus on enzymatic solutions for RNA manufacturing aligns with the industry's need for more efficient and scalable production methods.

Comparison to Industry Standards

• Codexis's revenue decline in 2023, largely due to the decrease in PAXLOVID related sales, is a significant deviation from the growth trajectory seen in many biotech companies focused on RNA therapeutics.
• Companies like Alnylam Pharmaceuticals, a leader in RNAi therapeutics, have shown consistent revenue growth, highlighting the competitive landscape Codexis is navigating.
• The development of the ECO Synthesis platform is a direct response to the industry's need for more efficient and scalable manufacturing processes, similar to efforts by companies like Aldevron in the custom development and manufacture of plasmid DNA, RNA and proteins.
• The licensing agreement with Roche for the dsDNA ligase is a strategic move to leverage their technology in a market where companies like Thermo Fisher Scientific are also active in providing tools for gene editing and RNA research.
• Codexis's projected return to growth in 2024 and positive cash flow by the end of 2026 is a critical target, as many biotech companies in the space are focused on achieving profitability and sustainable growth.

Stakeholder Impact

• Shareholders may be concerned about the significant net loss in 2023 but encouraged by the projected growth and positive cash flow outlook.
• Employees may be affected by the restructuring and headcount reductions mentioned in the report.
• Customers may benefit from the new ECO Synthesis platform and dsRNA ligase program.
• Suppliers may see changes in demand based on the company's strategic shifts.
• Creditors may be reassured by the new loan facility and the company's projected cash runway.

Next Steps

• Codexis plans to present a technical update on the ECO Synthesis manufacturing platform at the TIDES USA annual meeting in May 2024.
• The company will initiate early access customer testing of the ECO Synthesis manufacturing platform in the second half of 2024.
• Codexis plans to launch its dsRNA ligase program in the second half of 2024.
• They anticipate initial commercial licensing opportunities for the ECO Synthesis platform in 2025.
• Codexis expects a full commercial launch of the ECO Synthesis platform in 2026.

Key Dates

Keywords

enzyme engineering, ECO Synthesis, RNAi therapeutics, oligonucleotide synthesis, pharmaceutical manufacturing, biotherapeutics, dsDNA ligase, financial results, revenue, product revenue, research and development, net loss, cash flow, licensing agreement